Fig 1: Western blotting analysis(A) Western blot analysis showing protein levels of dystrophin-glycoprotein complex composing proteins, including α-DG, β-DG, α-actin, desmin, cTnT, and cardiac cTnI, in day 48 WT, Δ3–7, and Δ3–9 hiPSC-CMs. GAPDH was used as a loading control. (B) Quantification of protein expression in (A). (C) Western blot analysis showing protein levels of dystrophin-associated cardioprotective proteins, including AHNAK, Cypher, and CRYAB, in day 48 WT, Δ3–7, and Δ3–9 hiPSC-CMs. GAPDH was used as a loading control. (D) Quantification of protein expression in (C). (E) Western blot analysis of α-actin, desmin, TnT, AHNAK, Cypher, and CRYAB in WT and Δ3–9 hiPSC-CM lysates (input) and dystrophin IP samples. (F) Signal intensity ratio of α-actin, desmin, TnT, AHNAK, Cypher, and CRYAB to Dp427m in dystrophin IP samples in (E). Data are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005.
Fig 2: Family pedigree with black symbols indicating the affected members. The arrow indicates the proband (A). Electropherograms in the proband, his sister, and their father (B). Representative Western blot of controls and patient samples. Lane 1–4 staining with LDB3 (78 KDa and 32 KDa) and desmin. Lane 5–8 staining with LDB3 and myotilin. α-actinin-1 was used as loading control (C). Schematic representation of LDB3 protein structure with the indication of the already reported variants. The arrow shows the localization of our patient’s mutation in the PDZ domain (D).
Supplier Page from Abcam for Anti-LDB3 antibody